Last 445.50 GBp
Change Today +8.50 / 1.95%
Volume 35.8K
CLIN On Other Exchanges
As of 11:35 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

clinigen group plc (CLIN) Snapshot

436.50 GBp
Previous Close
437.00 GBp
Day High
446.75 GBp
Day Low
436.25 GBp
52 Week High
02/24/14 - 690.00 GBp
52 Week Low
08/8/14 - 359.25 GBp
Market Cap
Average Volume 10 Days
0.15 GBp
Shares Outstanding
2.22 GBp
Dividend Yield
Current Stock Chart for CLINIGEN GROUP PLC (CLIN)

Related News

No related news articles were found.

clinigen group plc (CLIN) Related Businessweek News

No Related Businessweek News Found

clinigen group plc (CLIN) Details

Clinigen Group plc provides specialty pharmaceutical products and services in the United Kingdom and internationally. The company’s Clinical Trials Supply segment sources and supplies commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. Its Specialty Pharmaceuticals segment manufactures and distributes Cardioxane to prevent the chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin use in advanced and/or metastatic adult breast cancer; Foscavir for the treatment of cytomegalovirus retinitis in HIV patients and Acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised patients; and Vibativ for the treatment of adults with hospital acquired pneumonia. The company’s Global Access Programs segment is involved in the consultancy, development, management, and implementation of global access programs that provide outsourced solutions for managing access to unlicensed, licensed, or end of lifecycle products. It serves patients, medical community, pharmaceutical companies, biotechnology companies, and contract research organizations. The company is headquartered in Burton-on-Trent, the United Kingdom.

87 Employees
Last Reported Date: 09/30/13

clinigen group plc (CLIN) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 661.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 346.0K GBP
Compensation as of Fiscal Year 2013.

clinigen group plc (CLIN) Key Developments

Clinigen Group plc Announces Earnings Results for the Year Ended June 30, 2014

Clinigen Group plc announced earnings results for the year ended June 30, 2014. For the year, the company’s like for like revenues on a constant currency basis up in excess of 7% on prior year and reported revenues not less than £126 million. Underlying EBITDA up at least 17% on prior year.

Clinigen Group Plc Proposes Interim Dividend Payable on March 28, 2014; Announces Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2013; Reaffirms Earnings Guidance for the Full Year of Fiscal 2014

Clinigen Group Plc announced that it is paying an interim dividend of 1.0 pence per share compared to 0.6 pence per share paid in the first half of fiscal 2013. The dividend will be payable on March 28, 2014 to all shareholders on the register at March 7, 2014. The company announced unaudited consolidated earnings results for the six months ended December 31, 2013. For the period, the company reported revenues of £61,761,000 compared with £61,007,000 for the same period a year ago. Profit from operations was £9,679,000 compared with £3,711,000 for the same period a year ago. Profit before tax was £9,602,000 compared with £3,655,000 for the same period a year ago. Profit attributable to owners of the company was £7,186,000 or 8.4 pence per diluted share compared with £2,328,000 or 2.9 pence per diluted share for the same period a year ago. Net cash flows from operating activities was £8,602,000 compared with £10,250,000 for the same period a year ago. Purchase of property, plant and equipments was £545,000 compared with £155,000 for the same period a year ago. Purchase of intangible fixed assets was £388,000. Underlying EBITDA up 20% to £12.5 million compared with £10.5 million for the same period a year ago. Underlying pre-tax profit 12% higher at £10.9 million compared with £9.7 million for the same period a year ago. Underlying earnings per share up 7.8% to 9.7 pence compared with 9.0 pence for the same period a year ago. Clinigen has delivered a good first half performance and remains on track to meet the Board's fiscal 2014 expectations.

Clinigen Group Plc Extends Accord Agreement to Capecitabine

Clinigen Group plc announced that its Clinical Trials Supply business has extended its exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare to include capecitabine, an orally administered chemotherapeutic tablet. Accord's capecitabine tablet adds to the company's EU portfolio of more than 15 injectable oncology drugs, including cisplatin, cytarabine, docetaxel, doxorubicin and fluorouracil currently distributed by Clinigen CTS to manufacturers, CROs, clinical re-packagers, and other specialist providers for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials. In June 2013 Clinigen CTS renewed its agreement with Accord to supply these products for a further two years and is the sole point of contact for all clinical trial supply enquiries and orders. The Capecitabine Accord tablet, which is a hybrid generic version of Xeloda, is available in a new strength of 300mg in addition to existing strengths of 150mg and 500mg. It was launched in Europe, a market worth almost USD 400 million, in December 2013. The chemotherapeutic is indicated for the treatment of a range of cancers including breast, colon, rectum and stomach and can be used in combination with other oncology products from the Accord portfolio supplied by Clinigen CTS.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLIN:LN 445.50 GBp +8.50

CLIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLIN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLIN Industry Range
Price/Earnings 22.9x
Price/Sales 2.9x
Price/Book 6.3x
Price/Cash Flow 22.4x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLINIGEN GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at